about
R-Ketorolac Targets Cdc42 and Rac1 and Alters Ovarian Cancer Cell Behaviors Critical for Invasion and MetastasisA phase 2 evaluation of irofulven as second-line treatment of recurrent or persistent intermediately platinum-sensitive ovarian or primary peritoneal cancer: a Gynecologic Oncology Group trial.Phase II clinical trial of ixabepilone in patients with recurrent or persistent platinum- and taxane-resistant ovarian or primary peritoneal cancer: a gynecologic oncology group study.A phase II evaluation of trabectedin in the treatment of advanced, persistent, or recurrent uterine leiomyosarcoma: a gynecologic oncology group study.Targeting the EGF receptor for ovarian cancer therapy.A pilot randomized control trial to evaluate pelvic floor muscle training for urinary incontinence among gynecologic cancer survivors.Analysis of genetic copy number changes in cervical disease progression.High incidence of ErbB3, ErbB4, and MET expression in ovarian cancer.Aberrant p16 methylation is a biomarker for tobacco exposure in cervical squamous cell carcinogenesis.Drug Repurposing from an Academic Perspective.Spatial Modeling of Drug Delivery Routes for Treatment of Disseminated Ovarian CancerA Novel Pharmacologic Activity of Ketorolac for Therapeutic Benefit in Ovarian Cancer Patients.Cervical neoplasia complicating pregnancy.Comorbidities and endometrial cancer survival in Hispanics and non-Hispanic whites.Pelvic masses.The quagmire of hCG and hCG testing in gynecologic oncology.Investigation of mammographic breast density as a risk factor for ovarian cancer.Pelvic floor disorders and sexual function in gynecologic cancer survivors: a cohort study.Silencing of HPV 18 oncoproteins With RNA interference causes growth inhibition of cervical cancer cells.A phase I trial of intraperitoneal GEN-1, an IL-12 plasmid formulated with PEG-PEI-cholesterol lipopolymer, administered with pegylated liposomal doxorubicin in patients with recurrent or persistent epithelial ovarian, fallopian tube or primary periGestational trophoblastic diseases: 4. Presentation with persistent low positive human chorionic gonadotropin test results.A case-control study of methylenetetrahydrofolate reductase polymorphisms in cervical carcinogenesis.Understanding the mechanisms of FHIT inactivation in cervical cancer for biomarker development.Changing trends in gestational trophoblastic disease.CCND1 polymorphism and age of onset of hepatoblastoma.Increasing Minority Enrollment Onto Clinical Trials: Practical Strategies and Challenges Emerge From the NRG Oncology Accrual Workshop.Summary of the 45th annual meeting on women's cancers.Detection of perimenopause or postmenopause human chorionic gonadotropin: an unnecessary source of alarm.I grew up watching the original Star Trek, amazed at the level of medical technology utilized in many episodes. Introduction.
P50
Q28265491-67B77C74-D6CF-4A9A-9989-238BF1918F8BQ30430457-5A67265E-1144-4522-8585-A04828287CBAQ30433670-5E970DF0-27FE-4820-9958-85C7086124EAQ33397625-5CC95121-56DB-43FF-AB8D-8977E9E4D4DFQ33570526-35469011-0F30-4EDA-955B-A4BDDA9CD11CQ33588000-33A37DC9-E54F-4431-A71A-58000AFB8AE2Q33659642-B6DDF643-3679-4F5B-A914-0CB30E855246Q34128962-DB9F1A41-1308-4FA7-98A7-B1FC17E5B0D9Q35712136-53751F9F-633E-4110-9C09-4847CDC8E268Q35774211-6527FC7A-9FAE-40E3-B2FD-5A580ED0CE37Q35882323-715C624A-CFA3-4D38-8285-187D3BDB594EQ36279606-5F0C8EF2-77A6-4D24-91E9-5159EC14F794Q36323690-677A3BEA-F096-44CF-8159-D01521C93424Q36487462-E674F6C7-9737-4844-B4D1-BEE722937D14Q37249900-9533DF73-2534-4AB6-9704-980E0FE8EC58Q37325207-F15E9136-83B9-4985-AE7B-1912C4DE541EQ37532651-7D0A8914-3E0D-4F98-B087-E5B9418590FAQ37708448-618D2C90-2CF3-409F-9A16-6FEC294EA97AQ38299944-E853F329-DF5D-482F-9E3A-6219533893C5Q38627539-694B65DD-F409-44BB-8D05-467009408372Q40332090-1D94CF0D-9BED-4276-AE2D-C91002D6FB83Q40371471-031AFD3A-C008-49B9-BAEB-495E10BE97A2Q40541253-D84E38DB-3652-483D-839F-998205F375F8Q46340714-7C132979-F8E3-4829-BE64-6E777907A155Q46931827-FADDE636-C017-441B-9EFD-37AC1A7D3C2CQ47214794-BC4EC59C-2364-4FC7-9663-E76FF81C81C1Q48071239-FBE6E029-D9C6-43BA-B29D-DD450E1360CDQ50801747-96F1942F-A896-4810-92FC-3460656A4DECQ51362957-586AACDD-3DB7-42AA-9379-AD36A50ECE33
P50
description
Amerikaans arts
@nl
médica estauxunidense
@ast
name
Carolyn Y. Muller
@ast
Carolyn Y. Muller
@ca
Carolyn Y. Muller
@en
Carolyn Y. Muller
@es
Carolyn Y. Muller
@fr
Carolyn Y. Muller
@nl
Carolyn Y. Muller
@sl
type
label
Carolyn Y. Muller
@ast
Carolyn Y. Muller
@ca
Carolyn Y. Muller
@en
Carolyn Y. Muller
@es
Carolyn Y. Muller
@fr
Carolyn Y. Muller
@nl
Carolyn Y. Muller
@sl
altLabel
Carolyn Y Muller
@en
Carolyn Y Muller
@fr
prefLabel
Carolyn Y. Muller
@ast
Carolyn Y. Muller
@ca
Carolyn Y. Muller
@en
Carolyn Y. Muller
@es
Carolyn Y. Muller
@fr
Carolyn Y. Muller
@nl
Carolyn Y. Muller
@sl
P106
P2038
Carolyn_Muller